Oncotarget

Research Papers:

Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI

Constantin Lapa _, Theresa Reiter, Malte Kircher, Andreas Schirbel, Rudolf A. Werner, Theo Pelzer, Carmen Pizarro, Dirk Skowasch, Lena Thomas, Ulrike Schlesinger-Irsch, Daniel Thomas, Ralph A. Bundschuh, Wolfgang R. Bauer and Florian C. Gärtner

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:77807-77814. https://doi.org/10.18632/oncotarget.12799

Metrics: PDF 784 views  |   HTML 1250 views  |   ?  


Abstract

Constantin Lapa1,*, Theresa Reiter2,3,*, Malte Kircher1, Andreas Schirbel1, Rudolf A. Werner1, Theo Pelzer2, Carmen Pizarro4, Dirk Skowasch4, Lena Thomas5, Ulrike Schlesinger-Irsch6, Daniel Thomas6, Ralph A. Bundschuh5, Wolfgang R. Bauer2,3,*, Florian C. Gärtner5,*

1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany

2Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany

3Comprehensive Heart Failure Center, University Würzburg, Würzburg, Germany

4Department of Internal Medicine II - Pneumology/Cardiology, University Hospital Bonn, Bonn, Germany

5Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

6Department of Radiology, University Hospital Bonn, Bonn, Germany

*These authors have contributed equally to this work

Correspondence to:

Constantin Lapa, email: lapa_c@ukw.de

Keywords: sarcoidosis, DOTATOC, SSTR, somatostatin receptor, PET

Received: September 01, 2016     Accepted: October 12, 2016     Published: October 21, 2016

ABSTRACT

Diagnosis of cardiac sarcoidosis is often challenging. Whereas cardiac magnetic resonance imaging (CMR) and positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) are most commonly used to evaluate patients, PET/CT using radiolabeled somatostatin receptor (SSTR) ligands for visualization of inflammation might represent a more specific alternative. This study aimed to investigate the feasibility of SSTR–PET/CT for detecting cardiac sarcoidosis in comparison to CMR.

15 patients (6 males, 9 females) with sarcoidosis and suspicion on cardiac involvement underwent SSTR-PET/CT imaging and CMR. Images were visually scored. The AHA 17-segment model of the left myocardium was used for localization and comparison of inflamed myocardium for both imaging modalities. In semi-quantitative analysis, mean (SUVmean) and maximum standardized uptake values (SUVmax) of affected myocardium were calculated and compared with both remote myocardium and left ventricular (LV) cavity.

SSTR-PET was positive in 7/15, CMR in 10/15 patients. Of the 3 CMR+/PET- subjects, one patient with minor involvement (<25% of wall thickness in CMR) was missed by PET. The remaining two CMR+/PET- patients displayed no adverse cardiac events during follow-up.

In the 17-segment model, PET/CT yielded 27 and CMR 29 positive segments. Overall concordance of the 2 modalities was 96.1% (245/255 segments analyzed). SUVmean and SUVmax in inflamed areas were 2.0±1.2 and 2.6±1.2, respectively. The lesion-to-remote myocardium and lesion-to-LV cavity ratios were 1.8±0.2 and 1.9±0.2 for SUVmean and 2.0±0.3 and 1.7±0.3 for SUVmax, respectively.

Detection of cardiac sarcoidosis by SSTR-PET/CT is feasible. Our data warrant further analysis in larger prospective series.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12799